SEC Comment Letter 0000000000-24-012011 to CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC.
Date: Oct. 28, 2024 · CIK: 0001133869 · Accession: 0000000000-24-012011
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282777
Letter
October 28, 2024 Linda Marbán Chief Executive Officer Capricor Therapeutics, Inc. 10865 Road to the Cure, Suite 150 San Diego, CA 92121 Re:Capricor Therapeutics, Inc. Registration Statement on Form S-3 Filed October 22, 2024 File No. 333-282777 Dear Linda Marbán: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Robert R. Carlson, Esq.
Show Raw Text
October 28, 2024
Linda Marbán
Chief Executive Officer
Capricor Therapeutics, Inc.
10865 Road to the Cure, Suite 150
San Diego, CA 92121
Re:Capricor Therapeutics, Inc.
Registration Statement on Form S-3
Filed October 22, 2024
File No. 333-282777
Dear Linda Marbán:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Robert R. Carlson, Esq.